M&A Deals: Monthly Monitor December

4 January 2016

(December) – Admitted that the mega US pharma giant Pfizer (NYSE: PFE) - Botox maker Allergan (NYSE: AGN) merger last month did set the bar very high and we thought rest of the year would just glide by reeling under the awe the deal garnered.

However, the pharma/ biotech sector isn’t quite done with the deals as reports surfaced indicating the US biotech company Baxalta (NYSE: BXLT) is looking at potential alternative suitors for a merger even as the company remains open to a deal with Ireland-headquartered Shire (LSE: SHP). There are also unconfirmed reports that Shire has made a fresh bid for Baxalta.

Shire has been pursuing USA-based Baxalta for nearly half-a-year now.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK